On the morning of the 15th, at the talent development conference in Dongtou District, Cheng Yi Pharmaceutical "Institute of Medicine and Mass Health" was officially launched, and Wang Jiaohu, Secretary of the District Party Committee, awarded the license. The company received 700000 yuan of construction subsidies in Dongtou District. On behalf of the company, General Manager Ren Bingjun signed cooperation agreements with two senior pharmaceutical talents at home and abroad, as well as a technology enterprise.
Recently, Zhejiang Cheng Yi Pharmaceutical Co., Ltd. won the honor of "exemplary organization in Wenzhou City that values talents and loves talents", which is the only one in Dongtou District; The development of Tolasemide raw materials and its formulations has won the first prize of the District Science and Technology Progress Award. Behind a series of "honors" is a series of measures taken by Cheng Yi Pharmaceutical to love and value talents.
Through strategies such as "inviting in and going out" and cultivating scarce talents for the company, Cheng Yi Pharmaceutical continuously breaks talent bottlenecks and gains development space. In March 2017, after the company was listed on the main board of the Shanghai Stock Exchange, the talent work was even faster, and its tentacles extended to domestic and foreign countries. The "National Thousand Talents Plan" experts, provincial "Thousand Talents Plan" experts and other senior talents, as well as talents needed by enterprises in all aspects, continued to gather.
On August 24 this year, the Science and Technology Department of Zhejiang Province announced on its official website that "Cheng Yi Pharmaceutical Research Institute" is a provincial scientific research project finalized by the Science and Technology Department of Zhejiang Province, the Development and Reform Commission of Zhejiang Province, and the Economic and Information Commission of Zhejiang Province. The Institute mainly researches and develops new products such as marine drugs, geriatrics drugs, anti-tumor drugs, traditional Chinese patent medicines and simple preparations, antidepressants, and secondary development of the company's existing products.
On August 28, Cheng Yi Pharmaceutical released an announcement at the Shanghai Stock Exchange. The announcement affirmed the further role of the research institute in the company's technological innovation. The announcement stated that the company will strengthen its research and development investment to add more momentum to sustainable development.
The reporter learned that Cheng Yi Pharmaceutical has signed six high-level talents who will contribute to the research institute. At the end of December, the preparation building and research and development building of Cheng Yi Pharmaceutical are about to start construction, which can further enrich the company's product line, enhance the competitiveness of the company's products in the field of pharmaceutical preparations, and increase the company's new profit growth points.
Cheng Yi Pharmaceutical loves and attracts talents, just starting and never stopping, "said Chairman Yan Yiyi.
News source: Zhejiang News Client
Reporter: Zhou Linzi